The global infection control market size was estimated at USD 52.38 billion in 2024, and is projected to reach USD 74.21 billion by 2030, growing at a CAGR of 6.1% from 2025 to 2030. The market is primarily driven by an increasing number of surgical & clinical procedures that require infection prevention.
Technological advancements in infection control have significantly enhanced the ability of healthcare providers to prevent and manage infections. Innovations such as automated disinfection systems, UV light technology, antimicrobial surface coatings, and advanced air filtration systems have demonstrated efficacy in reducing HAIs by up to 30% and is expected to contribute to the market growth. An increase in outsourcing sterilization services and the introduction of advanced sterilizing solutions are further contributing to the growth of the market for infection control. One of the important growth drivers is the increasing number of government initiatives to ensure highly intensive infection prevention. Government organizations are increasingly involved in issuing guidelines to promote awareness and efficient prevention measures globally, which is expected to contribute to market growth throughout the forecast period. For instance, the World Health Organization (WHO) has issued guidelines for preventing and controlling pandemic- and epidemic-prone acute respiratory diseases in healthcare. The guidelines range from standard precautions such as hand hygiene and usage of personal protective equipment to guidelines for disinfection and sterilization.
According to the article published by the National Library of Medicine in May 2024, Acute respiratory infections (ARIs) are a major global health burden, leading to around 4.25 million deaths annually. These infections lead to millions of outpatient visits each year, particularly affecting high-risk groups such as the elderly, young children, and individuals with chronic conditions such as asthma or heart disease.
Diseases such as pneumonia and infections such as bloodstream, urinary tract, surgical site, and MRSA constitute most hospital-acquired infections. Other major healthcare-associated infections (HAIs) include catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstream. One of the utmost concerns for the market is HAIs, which affect patient recovery; thereby, mortality rates are being significantly impacted globally. According to an article by NIH in April 2023, HAIs are the most common adverse effects in hospitals, leading to serious health risks, increased morbidity and mortality, and higher costs for patients, families, and healthcare systems. HAIs affect about 3.2% of hospitalized patients in the U.S. and 6.5% in the EU, with global prevalence expected to be even higher. This facilitates the need for effective infection prevention and control solutions.
According to a practical guide published by the WHO on preventing hospital-acquired infections, the increase in hospitalization duration with surgical infections was approximately eight days. These prolonged stays are predicted to significantly contribute to the overall costs incurred during the hospitalization period, thus, raising the clinical urgency for adopting infection prevention measures. It is presumed that prolonged hospital stay is also not economical for the hospitals and healthcare payers due to excessive usage of resources to treat the acquired infection. These additional costs are majorly generated through increased usage of drugs, additional diagnostic studies, and laboratory equipment, creating a resource allocation imbalance.
Technological advancements in infection control have significantly enhanced the ability of healthcare providers to prevent and manage infections. Innovations such as automated disinfection systems, UV light technology, antimicrobial surface coatings, and advanced air filtration systems have demonstrated efficacy in reducing HAIs by up to 30% and is expected to contribute to the market growth. An increase in outsourcing sterilization services and the introduction of advanced sterilizing solutions are further contributing to the growth of the market for infection control. One of the important growth drivers is the increasing number of government initiatives to ensure highly intensive infection prevention. Government organizations are increasingly involved in issuing guidelines to promote awareness and efficient prevention measures globally, which is expected to contribute to market growth throughout the forecast period. For instance, the World Health Organization (WHO) has issued guidelines for preventing and controlling pandemic- and epidemic-prone acute respiratory diseases in healthcare. The guidelines range from standard precautions such as hand hygiene and usage of personal protective equipment to guidelines for disinfection and sterilization.
According to the article published by the National Library of Medicine in May 2024, Acute respiratory infections (ARIs) are a major global health burden, leading to around 4.25 million deaths annually. These infections lead to millions of outpatient visits each year, particularly affecting high-risk groups such as the elderly, young children, and individuals with chronic conditions such as asthma or heart disease.
Diseases such as pneumonia and infections such as bloodstream, urinary tract, surgical site, and MRSA constitute most hospital-acquired infections. Other major healthcare-associated infections (HAIs) include catheter-associated urinary tract infections, ventilator-associated pneumonia, and catheter-related bloodstream. One of the utmost concerns for the market is HAIs, which affect patient recovery; thereby, mortality rates are being significantly impacted globally. According to an article by NIH in April 2023, HAIs are the most common adverse effects in hospitals, leading to serious health risks, increased morbidity and mortality, and higher costs for patients, families, and healthcare systems. HAIs affect about 3.2% of hospitalized patients in the U.S. and 6.5% in the EU, with global prevalence expected to be even higher. This facilitates the need for effective infection prevention and control solutions.
According to a practical guide published by the WHO on preventing hospital-acquired infections, the increase in hospitalization duration with surgical infections was approximately eight days. These prolonged stays are predicted to significantly contribute to the overall costs incurred during the hospitalization period, thus, raising the clinical urgency for adopting infection prevention measures. It is presumed that prolonged hospital stay is also not economical for the hospitals and healthcare payers due to excessive usage of resources to treat the acquired infection. These additional costs are majorly generated through increased usage of drugs, additional diagnostic studies, and laboratory equipment, creating a resource allocation imbalance.
Global Infection Control Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, the analyst has segmented the global infection control market on the basis of type, end use, and region:Type Outlook (Revenue, USD Billion, 2018 - 2030)
- Equipment
- Disinfectors
- Washers
- Flushes
- Endoscope Reprocessors
- Sterilization Equipment
- Heat Sterilization Equipment
- Low Temperature Sterilization Equipment
- Radiation Sterilization Equipment
- Filtration Sterilization Equipment
- Liquid Sterilization Equipment
- Others
- Services
- Contract Sterilization
- Ethylene Oxide Sterilization
- E-beam Sterilization
- Gamma Sterilization
- Others
- Infectious Waste Disposal
- Consumables
- Infectious Waste Disposal
- Disinfectants
- Sterilization Consumables
- Safety enhanced medical devices
- Personal Protective Equipment
- Others
End Use Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospitals
- Medical Device Companies
- Clinical Laboratories
- Pharmaceutical Laboratories
- Others
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Infection Control Market Variables, Trends & Scope
Chapter 4. Infection Control Market: Type Estimates & Trend Analysis
Chapter 5. Infection Control Market: End Use Estimates & Trend Analysis
Chapter 6. Infection Control Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- 3M
- Belimed AG
- O&M Halyard or its affiliates.
- GETINGE AB (publ) Corporate
- ASP
- MATACHANA
- Sterigenics U.S., LLC - A Sotera Health company
- MMM Group
- Medivators Inc.
- STERIS.
- Midmark Corporation.
- W&H